WATERTOWN, Mass., Sept. 28, 2016 -- For the seventh year in a row, pediatricians ranked temporal artery thermometry (TAT) number one in overall preference over any other thermometry method, according to a recent survey of physicians. Of the 268 survey respondents, 40.5 percent ranked TAT number one based on overall performance, compared to rectal, ear, oral and axillary thermometry. In addition, more than half (57.3 percent) of pediatricians ranked TAT number one in ease of use.
The new study further shows that Exergen is used and recommended more than any other thermometer brand – 42 percent of pediatricians use the Exergen TAT and 36 percent recommend it to their patients, ranking highest in both categories. In addition, the results show that nearly two-thirds of pediatricians (64.4 percent) who use or recommend Exergen temporal artery thermometers do so for patients of all ages, the highest percentage of any thermometer.
“We are pleased to see that pediatricians continue to embrace and recommend temporal artery thermometry over all other methods, and that the number of those physicians is steadily increasing,” said Dr. Francesco Pompei, CEO of Exergen Corporation. "With more than 60 clinical studies supporting its accuracy, physicians have come to trust and rely on the TemporalScanner. It is non-invasive, easy to use and accurate, which enhances the physician-patient bond."
Survey respondents noted strengths of temporal artery thermometry, including ease of use and accuracy. The survey also captured pediatricians' commentary about temporal artery thermometry. According to one physician respondent, "Temporal Artery Exergen has made my life very easy!" Another respondent said, “Temporal Artery is easy to use for nurse, patient and family.”
The survey was conducted by Pragmatic Research, Inc. and pediatricians were not told that it was sponsored by Exergen. The results were consistent with other independent research involving nurses and other healthcare professionals in various clinical settings.
ABOUT EXERGEN CORPORATION
Exergen Corporation is a recognized world leader in industrial and medical non-invasive temperature technology. The company manufactures and markets TemporalScanner thermometer models for hospitals and clinics, and consumer models sold in major retailers nationwide. Nearly two billion temperatures are taken each year with Exergen TemporalScanners in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, nurses, and mothers and is the #1 selling retail thermometer. The Exergen TemporalScanner’s performance is supported by more than 60 peer-reviewed published studies covering all ages from preterm infants to geriatrics, and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
Contact: Victoria Day Rosica Public Relations [email protected] P: 201.843.5600 F: 201.843.5680 21-00 Route 208 South, Suite 130 Fair Lawn, NJ 07410


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Instagram Outage Disrupts Thousands of U.S. Users
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



